Adipotide (FTPP): what it is and what the evidence says
An experimental conjugate of two peptides that recognizes prohibitin and ANXA2 on the blood vessels of white adipose tissue and triggers the death of those cells. Once the depot loses its blood supply, it is resorbed in animal models.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilizing stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Fat reduction, visceral fat, pharmacology case study.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
There are no published clinical trials. A first-in-human phase 1 trial (NCT01262664, MD Anderson Cancer Center) in metastatic prostate cancer with obesity enrolled four participants and was terminated at the principal investigator's request in January 2019 with no results posted.
The limitation that matters most
All efficacy evidence comes from mice and rhesus monkeys, where fat loss was rapid and dose-dependent kidney toxicity appeared, with tubular injury that reversed once the compound was withdrawn. Human pharmacokinetics are missing, a human safety profile is missing, and the 2012 objection that the treated primates also ate less was never settled.
Regulatory status
A research compound with no approval from any agency; clinical development was discontinued. It does not appear on the FDA list of bulk drug substances that may present significant safety risks, updated April 22, 2026. In sport, WADA section S0 covers substances with no approval in any country, prohibited at all times.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
The dose-dependent kidney toxicity seen in primates is its defining safety feature, with tubular injury that reversed once the compound was withdrawn. Clinical development was never completed, so its profile in people remains uncharacterized.
It is a research compound with no established use in people, so any consideration belongs with a professional and within a research setting.
What this page cannot give you
A reference page can take you this far. You know what Adipotide (FTPP) is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Reversal of obesity by targeted ablation of adipose tissuepreclinical Nat Med · 2004 · PMID 15133506 →
- A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeyspreclinical Sci Transl Med · 2011 · PMID 22072637 →
- Comment on 'a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys'review Sci Transl Med · 2012 · PMID 22539771 →
- Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endotheliumpreclinical Diabetes · 2012 · PMID 22733798 →
- A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medicationpreclinical J Control Release · 2013 · PMID 23871959 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Adipotide (FTPP) or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Adipotide (FTPP)?
An experimental conjugate of two peptides that recognizes prohibitin and ANXA2 on the blood vessels of white adipose tissue and triggers the death of those cells. Once the depot loses its blood supply, it is resorbed in animal models. It is studied within the area of metabolic.
Is there human evidence for Adipotide (FTPP)?
There are no published clinical trials. A first-in-human phase 1 trial (NCT01262664, MD Anderson Cancer Center) in metastatic prostate cancer with obesity enrolled four participants and was terminated at the principal investigator's request in January 2019 with no results posted.
Is it approved by any health agency?
A research compound with no approval from any agency; clinical development was discontinued. It does not appear on the FDA list of bulk drug substances that may present significant safety risks, updated April 22, 2026. In sport, WADA section S0 covers substances with no approval in any country, prohibited at all times.
What is the dose of Adipotide (FTPP)?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Adipotide (FTPP) is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.